drugset / Trial / NCT00984802
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV) injection, and to evaluate efficacy on the basis of the changes seen in the cardiac biomarkers and continuous electrocardiography (ECG) monitoring. Additionally, correlation of the levels/changes in the biomarkers and the pharmacokinetic evaluations of the drug will be explored.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-03
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMX-2043 | Small molecule | 0.8 mg/kg | Intravenous |
| Subject | CMX-2043 | Small molecule | 1.6 mg/kg | Intravenous |
| Subject | CMX-2043 | Small molecule | 2.4 mg/kg | Intravenous |